Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval
Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval is drawing significant interest across the industry.
Eli Lilly CFO Lucas Montarce said on Monday it is preparing ?to launch its new oral obesity drug, ?orforglipron, in the United States as early as the second quarter of this year, once it gets approval ?from the Food and Drug Administration.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Transgender men sue Kansas over new anti-trans law on bathrooms, IDs
- This former Microsoft PM thinks she can unseat CyberArk in 18 months
- Intuitive Expands Investment and Footprint in Europe
- Guinness World Record for largest Saudi Ardah performance set at Riyadh's Qasr Al-Hukm
Source: Original →